Studies

HARP-X

Healing of Antibiotic Refractory Pouchitis with Xeljanz HARP-X is a prospective multi-centre, open label induction and randomized maintenance pilot study of Tofacitinib in subjects with chronic, antibiotic refractory or dependent pouchitis. The primary objective is to determine the effect of tofacitinib maintenance therapy on endoscopic……

GOAL-ARC

Golimumab dose Optimisation to Adequate Levels to Achieve Response in Colitis GOAL-ARC is a nationwide multi-centred investigator initiated randomized control trial to evaluate the use of personalized Golimumab (GLM) dose adjustment in ulcerative colitis. The primary objective is to ascertain if dose adjustment of GLM, based……

I-CARE

IBD Cancer and Serious Infections in Europe     I-CARE is the first observational European prospective cohort study that will provide unique information (safety, efficacy, risk-benefit ratio, and healthcare costs) on the long-term use of recommended therapy in IBD, using a predefined standardized follow-up. These real world data will be used……

MOBIDIC

Molecular Biomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection study In Crohn’s disease patients (MOBIDIC) Abnormal colonization of the gastrointestinal tract by Enterobacteriaceae might play a role in the development of Crohn’s Disease (CD). Clearance of this bacteria could represent a new therapeutic strategy……

SECURE-IBD

Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) is an international, pediatric and adult database to monitor and report on outcomes of COVID-19 occurring in IBD patients. With the collaboration of our entire IBD community, we will rapidly be able to define the impact of COVID-19 on patients with IBD……

STEIG

STEIG is a retrospective study of clinical outcomes of off licence treatment with Ustekinumab for Crohn’s Disease. Ustekinumab (Stelara) is a monoclonal antibody against the common p40 subunit of IL-12 and IL-23 and has recently been approved for (intravenous) induction and (subcutaneous) maintenance treatment of patients……

VARIATION

VARIATION was a prospective multi-centre Irish study aiming to determine the impact of IBD and various medications for treatment of IBD on antibody responses to vaccination against COVID-19. Background and aims: Evidence suggests patients with inflammatory bowel disease [IBD] receiving TNF antagonists have attenuated response to……

TOAST-IBD

TOAST-IBD is a multi-centre Irish study, aiming to develop core outcomes measures for intervention studies in patients with IBD who have stomas. Patients with stomas are excluded from clinical trials of investigational medicinal products, primarily because of the difficulty in calculating disease activity scores such as Crohn’s Disease Activity Index…..

BODPOD-IBD

This is a pilot study with an aim of recruiting 30 patients and 15 healthy controls over a period of 12 months with 6 months of prospective follow-up and 24 months of retrospective analysis. After initial analysis, a more specific sample size can be calculated for validation…